药代动力学/药效学建模中的时变协变量、过度调整偏倚与中介作用 - Suppr

Suppr

超能文献

Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling.

作者信息

Goulooze Sebastiaan Camiel, Snelder Nelleke

机构信息

LAP&P Consultants BV, Leiden, The Netherlands.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1285-1288. doi: 10.1002/psp4.13200. Epub 2024 Jul 16.

DOI:10.1002/psp4.13200

PMID:39010750

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11330179/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/11330179/c0361c2dba30/PSP4-13-1285-g001.jpg

相似文献

Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling.药代动力学/药效学建模中的时变协变量、过度调整偏倚与中介作用

CPT Pharmacometrics Syst Pharmacol. 2024 Aug;13(8):1285-1288. doi: 10.1002/psp4.13200. Epub 2024 Jul 16.

Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.群体药代动力学协变量模型的效能、选择偏倚及预测性能

J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34. doi: 10.1023/b:jopa.0000034404.86036.72.

Pharmacokinetic pharmacodynamic modeling of analgesics and sedatives in children.儿童镇痛镇静药物的药代动力学药效学模型。

Paediatr Anaesth. 2023 Oct;33(10):781-792. doi: 10.1111/pan.14712. Epub 2023 Jun 21.

Overadjustment bias and unnecessary adjustment in epidemiologic studies.流行病学研究中的过度调整偏倚与不必要的调整

Epidemiology. 2009 Jul;20(4):488-95. doi: 10.1097/EDE.0b013e3181a819a1.

Methodological issues in pharmacokinetic-pharmacodynamic modelling.药代动力学-药效学建模中的方法学问题。

Clin Pharmacokinet. 1998 Aug;35(2):151-66. doi: 10.2165/00003088-199835020-00004.

Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.利用效应室浓度达峰时间结合药代动力学和药效学。

Anesthesiology. 2003 Aug;99(2):324-33. doi: 10.1097/00000542-200308000-00014.

Overadjustment bias in systematic reviews and meta-analyses of socio-economic inequalities in health: a meta-research scoping review.系统评价和荟萃分析中健康社会经济不平等的过度调整偏差：元研究范围综述。

Int J Epidemiol. 2024 Feb 1;53(1). doi: 10.1093/ije/dyad177.

Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.帕金森病患者口服左旋多巴的群体药代动力学和药效学

Eur J Clin Pharmacol. 1996;51(1):59-67. doi: 10.1007/s002280050161.

Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.丙泊酚用于重症患者长期镇静的群体药代动力学和药效学建模：丙泊酚6%与丙泊酚1%的比较

Clin Pharmacol Ther. 2002 Dec;72(6):670-84. doi: 10.1067/mcp.2002.129500.

Pharmacokinetic-pharmacodynamic modeling in anesthesia, intensive care and pain medicine.麻醉、重症监护与疼痛医学中的药代动力学-药效学建模

Curr Opin Anaesthesiol. 2009 Aug;22(4):463-8. doi: 10.1097/ACO.0b013e32832c3c6c.

引用本文的文献

Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.支持肿瘤学研发决策的联合肿瘤大小-总生存建模与模拟框架的开发。

CPT Pharmacometrics Syst Pharmacol. 2025 Jun;14(6):1006-1017. doi: 10.1002/psp4.70002. Epub 2025 Feb 21.

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.关于使用肿瘤大小-总生存模型进行条件模拟以支持肿瘤药物开发的教程。

CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):640-650. doi: 10.1002/psp4.70003. Epub 2025 Feb 21.

本文引用的文献

Covariate modeling in pharmacometrics: General points for consideration.药物代谢动力学中的协变量建模：一般注意事项。

CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):710-728. doi: 10.1002/psp4.13115. Epub 2024 Apr 2.

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.非奈利酮在慢性肾脏病合并 2 型糖尿病患者中的药代动力学和药效学：基于 FIGARO-DKD 和 FIDELIO-DKD 的研究结果。

Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30.

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation.儿科治疗学开发的创新：桥接生物标志物在儿科外推中的应用原则。

Ther Innov Regul Sci. 2023 Jan;57(1):109-120. doi: 10.1007/s43441-022-00445-6. Epub 2022 Sep 3.

Mediation analysis methods used in observational research: a scoping review and recommendations.观察性研究中中介分析方法的应用：范围综述及建议。

BMC Med Res Methodol. 2021 Oct 25;21(1):226. doi: 10.1186/s12874-021-01426-3.

Revisiting Overadjustment Bias.重新审视过度调整偏差。

Epidemiology. 2021 Sep 1;32(5):e22-e23. doi: 10.1097/EDE.0000000000001377.

Mediation Analysis: A Practitioner's Guide.中介分析：实践者指南。

Annu Rev Public Health. 2016;37:17-32. doi: 10.1146/annurev-publhealth-032315-021402. Epub 2015 Nov 30.

Mediation analysis in epidemiology: methods, interpretation and bias.流行病学中的中介分析：方法、解释和偏倚。

Int J Epidemiol. 2013 Oct;42(5):1511-9. doi: 10.1093/ije/dyt127. Epub 2013 Sep 9.

Basic concepts in population modeling, simulation, and model-based drug development.群体建模、模拟和基于模型的药物研发的基本概念。

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e6. doi: 10.1038/psp.2012.4.

Overadjustment bias and unnecessary adjustment in epidemiologic studies.流行病学研究中的过度调整偏倚与不必要的调整

Epidemiology. 2009 Jul;20(4):488-95. doi: 10.1097/EDE.0b013e3181a819a1.

Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.群体药代动力学-药效学分析中时变协变量的模型

Br J Clin Pharmacol. 2004 Oct;58(4):367-77. doi: 10.1111/j.1365-2125.2004.02170.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验